Literature DB >> 26246802

Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells.

Qing-Yi Lu1, Lifeng Zhang1, Jennifer K Yee2, Vay-Liang W Go1, Wai-Nang Lee2.   

Abstract

Lactate dehydrogenase A (LDHA) is the enzyme that converts pyruvate to lactate and oxidizes the reduced form of nicotinamide adenine dinucleotide (NADH) to NAD+. Several human cancers including the pancreas display elevated expression of LDHA. Because of its essential role in cancer metabolism, LDHA has been considered to be a potential target for cancer therapy. Recently, we have shown that a green tea extract significantly down-regulated LDHA in HPAF-II pancreatic cancer cells using global proteomics profiling. The present study is to investigate how EGCG, a major biological active constituent of green tea, targets the metabolism of human pancreatic adenocarcinoma MIA PaCa-2 cells. We compared the effect of EGCG to that of oxamate, an inhibitor of LDHA, on the multiple metabolic pathways as measured by extracellular lactate production, glucose consumption, as well as intracellular aspartate and glutamate production, fatty acid synthesis, acetyl-CoA, RNA ribose and deoxyribose. Specific metabolic pathways were studied using [1, 2-13C2]-d-glucose as the single precursor metabolic tracer. Isotope incorporations in metabolites were analyzed using gas chromatography/mass spectrometry (GC/MS) and stable isotope-based dynamic metabolic profiling (SiDMAP). We found that the EGCG treatment of MIA PaCa-2 cells significantly reduced lactate production, anaerobic glycolysis, glucose consumption and glycolytic rate that are comparable to the inhibition of LDHA by oxamate treatment. Significant changes in intracellular glucose carbon re-distribution among major glucose-utilizing macromolecule biosynthesis pathways in response to EGCG and oxamate treatment were observed. The inhibition of LDHA by EGCG or oxamate impacts on various pathways of the cellular metabolic network and significantly modifies the cancer metabolic phenotype. These results suggest that phytochemical EGCG and LDHA inhibitor oxamate confer their anti-cancer activities by disrupting the balance of flux throughout the cellular metabolic network.

Entities:  

Keywords:  EGCG; human pancreatic cancer MIA PaCa-2 cells; oxamate; tracer based metabolomics

Year:  2015        PMID: 26246802      PMCID: PMC4523095          DOI: 10.1007/s11306-014-0672-8

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  40 in total

1.  The role of glycolysis in the growth of tumor cells. II. The effect of oxamic acid on the growth of HeLa cells in tissue culture.

Authors:  J PAPACONSTANTINOU; S P COLOWICK
Journal:  J Biol Chem       Date:  1961-02       Impact factor: 5.157

Review 2.  Complete mass spectra of N-trifluoroacetyl-n-butyl esters of amino acids.

Authors:  K R Leimer; R H Rice; C W Gehrke
Journal:  J Chromatogr       Date:  1977-08-21

3.  Effects of (-)-epigallocatechin-3-O-gallate on expression of gluconeogenesis-related genes in the mouse duodenum.

Authors:  Kensuke Yasui; Hiroki Tanabe; Noriyuki Miyoshi; Takuji Suzuki; Shingo Goto; Kyoko Taguchi; Yoko Ishigami; Noriko Paeng; Ryuuta Fukutomi; Shinjiro Imai; Mamoru Isemura
Journal:  Biomed Res       Date:  2011-10       Impact factor: 1.203

4.  Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth.

Authors:  L G Boros; S Bassilian; S Lim; W N Lee
Journal:  Pancreas       Date:  2001-01       Impact factor: 3.327

5.  Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.

Authors:  J Boren; M Cascante; S Marin; B Comín-Anduix; J J Centelles; S Lim; S Bassilian; S Ahmed; W N Lee; L G Boros
Journal:  J Biol Chem       Date:  2001-08-06       Impact factor: 5.157

6.  Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells.

Authors:  L G Boros; J S Torday; S Lim; S Bassilian; M Cascante; W N Lee
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

7.  PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells.

Authors:  Shi Liu; Xiao-Jie Wang; Ying Liu; Yun-Fu Cui
Journal:  Am J Chin Med       Date:  2013       Impact factor: 4.667

Review 8.  Tumor suppressors and cell metabolism: a recipe for cancer growth.

Authors:  Russell G Jones; Craig B Thompson
Journal:  Genes Dev       Date:  2009-03-01       Impact factor: 11.361

9.  Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate.

Authors:  Moriatsu Takada; Yoichiro Nakamura; Tamio Koizumi; Hirochika Toyama; Takashi Kamigaki; Yasuyuki Suzuki; Yoshifumi Takeyama; Yoshikazu Kuroda
Journal:  Pancreas       Date:  2002-07       Impact factor: 3.327

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  16 in total

1.  Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.

Authors:  Ran Wei; Limin Mao; Ping Xu; Xinghai Zheng; Robert M Hackman; Gerardo G Mackenzie; Yuefei Wang
Journal:  Food Funct       Date:  2018-11-14       Impact factor: 5.396

2.  The Warburg effect: a balance of flux analysis.

Authors:  B Vaitheesvaran; J Xu; J Yee; Lu Q-Y; V L Go; G G Xiao; W N Lee
Journal:  Metabolomics       Date:  2015-08       Impact factor: 4.290

Review 3.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 4.  Chinese Herbs Interfering with Cancer Reprogramming Metabolism.

Authors:  Zhangfeng Zhong; William W Qiang; Wen Tan; Haotian Zhang; Shengpeng Wang; Chunming Wang; Wenan Qiang; Yitao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-05       Impact factor: 2.629

5.  Jolkinolide B induces apoptosis and inhibits tumor growth in mouse melanoma B16F10 cells by altering glycolysis.

Authors:  Caixia Gao; Xinyan Yan; Bo Wang; Lina Yu; Jichun Han; Defang Li; Qiusheng Zheng
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

6.  Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.

Authors:  S Battini; F Faitot; A Imperiale; A E Cicek; C Heimburger; G Averous; P Bachellier; I J Namer
Journal:  BMC Med       Date:  2017-03-16       Impact factor: 8.775

Review 7.  KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism.

Authors:  Isaac James Muyinda; Jae-Gwang Park; Eun-Jung Jang; Byong-Chul Yoo
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

8.  Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil.

Authors:  Jung Ho Han; MinJeong Kim; Hyeon Jin Kim; Se Bok Jang; Sung-Jin Bae; In-Kyu Lee; Dongryeol Ryu; Ki-Tae Ha
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

9.  In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity.

Authors:  Sainan Li; Liwei Wu; Jiao Feng; Jingjing Li; Tong Liu; Rong Zhang; Shizan Xu; Keran Cheng; Yuqing Zhou; Shunfeng Zhou; Rui Kong; Kan Chen; Fan Wang; Yujing Xia; Jie Lu; Yingqun Zhou; Weiqi Dai; Chuanyong Guo
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

10.  MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A.

Authors:  Daozhang Yuan; Shunsheng Zheng; Liyan Wang; Jing Li; Jianan Yang; Bin Wang; Xiong Chen; Xiaobo Zhang
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.